Melatonin in Cancer Patients and in Tumor-Bearing Animals

  • Christian Bartsch
  • Hella Bartsch
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 467)

Abstract

A review of findings is given which relate to the levels of circulating melatonin as well as the urinary excretion of its main peripheral metabolite 6-sulphatoxymelatonin (aMT6s) in patients with different types of cancer as well as in tumor-bearing animals.

Clinical results show that circulating melatonin tends to be depressed in patients with primary tumors of different histological types including both endocrine-dependent (mammary, endometrial, prostate cancer) and endocrine-independent tumors (lung, gastric, colorectal cancer). Reduction of melatonin is most pronounced in patients with advanced localized primary tumors, such as mammary and prostate cancer where a clear negative correlation with tumor-size exists. The phenomenon of a reduction of circulating melatonin appears to be a transient one since patients with recidives show a normalization of melatonin. Surgical removal of the primary tumor does, however, not lead to normalization indicating that complex systemic changes appear to be involved in the down-regulation of melatonin. It is unclear at present, whether circulating melatonin is depleted in cancer patients due to a reduced production by the pineal gland or due to certain peripheral metabolic processes, although no evidence for an enhanced hepatic degradation to aMT6s, the main peripheral metabolite of melatonin, was found. The reduction of circulating melatonin is accompanied by neuroendocrine changes affecting the circadian secretion of the adenohypophyseal hormones prolactin, somatotropin and thyroid-stimulating hormone. In contrast to the above-described types of tumors many patients with ovarian cancer show highly elevated levels of melatonin perhaps due to the production of tissue-specific growth factors that could affect pineal melatonin secretion.

Experiments with tumor-bearing animals clearly demonstrate that nocturnal circulating melatonin is modulated due to malignant growth. Detailed investigations with chemically induced mammary tumors in rats and serial transplants derived thereof show that slow-growing and well-differentiated tumors containing epithelial cell elements (adenocar-cinomas and carcinosarcomas) lead to an enhanced production of melatonin involving activation of the rate-limiting enzyme of pineal melatonin biosynthesis (serotonin N-acetyltransferase) probably due to elevation of the sympathetic tone in response to a stimulation of the cellular immune system by malignant growth. As opposed to that nocturnal melatonin is depleted in animals with fast-growing mammary tumor transplants when myoepithelial-mesenchymal conversion leads to pure sarcomas. The reduction of melatonin appears to be due to either a reduced availability of the precursor amino acid tryptophan because of a glucocorticoid-induced activation of the hepatic enzyme tryptophan 2,3-dioxygenase or a direct peripheral degradation of melatonin via indoleamine 2,3-dioxygenase expressed in tumor and/or other tissues.

The significance of these clinical and experimental findings relating to melatonin is discussed both in terms of their practical application as a possible tumor marker and from a theoretical point of view to understand better the mechanisms involved in complex hosttumor interactions involving the neuroimmunoendocrine network.

Keywords

Depression Estrogen Adenocarcinoma Cortisol Serotonin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aldhous, M.E. and Arendt, J., 1988, Radioimmunoassay for 6-sulphatoxymelatonin in urine using an iodinated tracer, Ann. Clin. Biochem. 25:298–303.PubMedGoogle Scholar
  2. Anisimov, V.N., Popovich, I.G., and Zabezhinski, M.A., 1997, Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats, Carcinogenesis 18:1549–1553.PubMedCrossRefGoogle Scholar
  3. Anisimov, V.N., Kvetnoy, I.M., Chumakova, N.K., Kvetnaya, T.V., Molotkov, A.O., Pogudina, N.A., Popovich, I.G., Popuchiev, V.V., Zabezhinski, M.A., Bartsch, H., and Bartsch, C., 1999, Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors, Exp. Toxic. Pathol. 51:47–52.CrossRefGoogle Scholar
  4. Arendt, J., 1978, Melatonin assays in body fluids, J. Neural Transm. Suppl. 13:265–278.PubMedGoogle Scholar
  5. Arendt, J., Bojkowski, C., Franey, C., Wright, J., and Marks, V., 1985, Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine: abolition of the urinary 24-hour rhythm with atenolol, J. Clin. Endocrinol. Metab. 60:1166–1173.PubMedCrossRefGoogle Scholar
  6. Barni, S., Lissoni, P., Paolorossi, F., Crispino, S., Archili, C., and Tancini, G., 1990, A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates, Tumori 76:58–60.PubMedGoogle Scholar
  7. Barone, R.M. and Das Gupta, T.K., 1970, Role of pinealectomy on Walker 256 carcinoma in rats, J. Surg. Oncol. 2:313–322.PubMedCrossRefGoogle Scholar
  8. Bartsch, C., Bartsch, H., Jain, A.K., Laumas, K.R., and Wetterberg, L., 1981, Urinary melatonin levels in human breast cancer patients, J. Neural Transm. 52:281–294.PubMedCrossRefGoogle Scholar
  9. Bartsch, C., Bartsch, H., Flüchter, S.H., Harzmann, R., Bichler, K.-H., and Gupta, D., 1982, Serum melatonin and cortisol rhythms of patients with benign and malignant tumours of the prostate, Neuroendocrinol. Lett. 4:176. (Abstract).Google Scholar
  10. Bartsch, C., Bartsch, H., Flüchter, S.H., Harzmann, R., Attanasio, A., Bichler, K.-H., and Gupta, D., 1983, Circadian rhythms of serum melatonin, prolactin and growth hormone in patients with benign and malignant tumors of the prostate and in non-tumor controls, Neuroendocrinol. Lett. 5:377–386.Google Scholar
  11. Bartsch, C., Bartsch, H., Flüchter, S.H., Attanasio, A., and Gupta, D., 1985, Evidence for modulation of melatonin secretion in men with benign and malignant tumors of the prostate: relationship with the pituitary hormones, J. Pineal Res. 2:121–132.PubMedCrossRefGoogle Scholar
  12. Bartsch, C., Bartsch, H., Flüchter, S.-H., Attanasio, A., and Gupta, D., 1986, Melatonin rhythms in prostate cancer patients: effect of operation and hormone treatment, J. Neural Transm. Suppl. 21:491 (Abstract).Google Scholar
  13. Bartsch, C., 1988, Untersuchungen zur Funktion der Zirbeldrüse und ihrer Beziehung zum endokrinen System im Brust-und Prostatacarcinom: tierexperimentelle und humanbiologische Untersuchungen, ph.D. Thesis at the Faculty of Chemistry and Pharmacy, University of Tübingen, Tübingen.Google Scholar
  14. Bartsch, C., Bartsch, H., Fuchs, U., Lippert, T.H., Bellmann, O., and Gupta, D., 1989, Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors, Cancer 64:426–433.PubMedCrossRefGoogle Scholar
  15. Bartsch, C., Bartsch, H., and Gupta, D., 1990, Pineal melatonin synthesis and secretion during induction and growth of mammary cancer in female rats, in: Neuroendocrinology: New Frontiers, (D. Gupta, H.A. Wollmann and M.B. Ranke, eds.), pp. 326–332, Brain Research Promotion, London, Tübingen.Google Scholar
  16. Bartsch, C., Bartsch, H., Bellmann, O., and Lippert, T.H., 1991, Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolism, Cancer 67:1681–1684.PubMedCrossRefGoogle Scholar
  17. Bartsch, C., Bartsch, H., Schmidt, A., Ilg, S., Bichler, K.H., and Flüchter, S.H., 1992, Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations, Clin. Chim. Acta 209:153–167.PubMedCrossRefGoogle Scholar
  18. Bartsch, C. and Bartsch, H., 1994, Melatonin secretion in oncological patients: current results and methodological considerations, in: Advances in Pineal Research, Vol.7, (G.J.M. Maestroni, A. Conti and R.J. Reiter, eds.), pp. 283–301, John Libbey, London.Google Scholar
  19. Bartsch, C., Bartsch, H., Flüchter, S.H., Mecke, D., and Lippert, T.H., 1994, Diminished pineal function coincides with disturbed circadian endocrine rhythmicity in untreated primary cancer patients. Consequence of premature aging or of tumor growth? Ann. N. Y. Acad. Sci. 719:502–525.PubMedCrossRefGoogle Scholar
  20. Bartsch, C., Bartsch, H., Buchberger, A., Rokos, H., Mecke, D., and Lippert, T.H., 1995, Serial transplants of DMBA-induced mammary tumors in Fischer rats as model system for human breast cancer. IV Parallel changes of biopterin and melatonin indicate interactions between the pineal gland and cellular immunity in malignancy, Oncology 52:278–283.PubMedCrossRefGoogle Scholar
  21. Bartsch, C., Bartsch, H., Karenovics, A., Franz, H., Peiker, G., and Mecke, D., 1997a, Nocturnal urinary 6-sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age-matched controls and shows negative correlation with tumor-size, J. Pineal Res. 23:53–58.PubMedCrossRefGoogle Scholar
  22. Bartsch, C., Kvetnoy, I., Kvetnaia, T., Bartsch, H., Molotkov, A., Franz, H., Raikhlin, N., and Mecke, D., 1997b, Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer, J. Pineal Res. 23:90–96.PubMedCrossRefGoogle Scholar
  23. Bartsch, C., Bartsch, H., Bichler, K.-H., and Flüchter, S.-H., 1998, Prostate cancer and tumor stage-dependent circadian neuroendocrine disturbances, Aging Male 1:188–199.CrossRefGoogle Scholar
  24. Bartsch, C., Bartsch, H., Buchberger, A., Stieglitz, A., Effenberger-Klein, A., Kruse-Jarres, J.D., Besenthal, I., Rokos, H., and Mecke, D., 1999, Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer. VI. The role of different forms of tumor-associated stress for the regulation of pineal melatonin secretion, Oncology 56(2):169–176.PubMedCrossRefGoogle Scholar
  25. Bartsch, C., Szadowska, A., Karasek, M., Bartsch, H., Geppert, M., and Mecke, D., 1999, Serial transplants of DMBA-induced mammary tumors in Fischer rats as model system for human breast cancer. V. Myoepithelial-mesenchymal conversion during passaging as possible cause for modulation of pineal-tumor interaction, Exp. Toxic. Pathol. (In Press).Google Scholar
  26. Bartsch, H. and Bartsch, C., 1981, Effect of melatonin on experimental tumors under different photoperiods and times of administration, J. Neural Transm. 52:269–279.PubMedCrossRefGoogle Scholar
  27. Bartsch, H., Bartsch, C., Mecke, D., and Lippert, T.H., 1993, The relationship between the pineal gland and cancer: seasonal aspects, in: Light and Biological Rhythms in Man, (L. Wetterberg, ed.), pp. 337–347, Pergamon Press, Oxford.Google Scholar
  28. Bartsch, H., Bartsch, C., Mecke, D., and Lippert, T.H., 1994a, Differential effect of melatonin on early and advanced passages of a DMBA-induced mammary carcinoma in the female rat, in: Advances in Pineal Research, Vol.7, (G.J.M. Maestroni, A. Conti and R.J. Reiter, eds.), pp. 247–252, John Libbey, London.Google Scholar
  29. Bartsch, H., Bartsch, C., Mecke, D., and Lippert, T.H., 1994b, Seasonality of pineal melatonin production in the rat: possible synchronization by the geomagnetic field, Chronobiol. Int. 11:21–26.PubMedCrossRefGoogle Scholar
  30. Bergmann, W. and Engel, P., 1950, Über den Einflu von Zirbelextrakten auf Tumoren bei weien Mäusen und bei Menschen, Wien. Klin. Wochenschr. 62:79–82.Google Scholar
  31. Brzezinski, A., Seibel, M.M., Lynch, H.J., Deng, M.H., and Wurtman, R.J., 1987, Melatonin in human preovulatory follicular fluid, J. Clin. Endocrinol. Metab. 64:865–867.PubMedCrossRefGoogle Scholar
  32. Cardinali, D.P., 1984, Neural-hormonal integrative mechanisms in the pineal gland and superior cervical ganglia, in: The Pineal Gland, (R.J. Reiter, ed.), pp. 83–107, Raven Press, New York.Google Scholar
  33. Colombo, F., Iannotta, F., Fachinetti, A., Giuliani, F., Cornaggia, M., Finzi, G., Mantero, G., Fraschini, F., Malesci, A., and Bersani, M., 1991, Changes in hormonal and biochemical parameters in gastric adenocarcinoma, Minerva. Endocrinol. 16:127–139.PubMedGoogle Scholar
  34. Danforth, D.N.J., Tamarkin, L., Mulvihill, J.J., Bagley, C.S., and Lippman, M.E., 1985, Plasma melatonin and the hormone-dependency of human breast cancer, J. Clin. Oncol. 3:941–948.PubMedGoogle Scholar
  35. Engel, P., 1935, Wachstumsbeeinflussende Hormone und Tumorwachstum, Z. Krebsforsch. 41:488–496.CrossRefGoogle Scholar
  36. Feigelson, P. and Greengard, O., 1962, Immunochemical evidence for increased titers of liver pyrrolase during substrate and hormonal enzyme induction, J. Biol. Chem. 237:3714–3717.Google Scholar
  37. Gilad, E., Matzkin, H., and Zisapel, N., 1997, Interplay between sex steroids and melatonin in regulation of human benign prostate epithelial cell growth, J. Clin. Endocrinol. Metab. 82:2535–2541.PubMedCrossRefGoogle Scholar
  38. Goustin, A.S., Leof, E.B., Shipley, G.D., and Moses, H.L., 1986, Growth factors and cancer, Cancer Res. 46:1015–1029.PubMedGoogle Scholar
  39. Grin, W. and Grünberger, W., 1998, A significant correlation between melatonin deficiency and endometrial cancer, Gynecol. Obstet. Invest. 45:62–65.PubMedCrossRefGoogle Scholar
  40. Hoffmann, G., Pollow, K., Kreienberg, R., Hütz, R., Schaffrath, M., Strittmatter, H.-J., Weickel, W., and Pollow, B., 1996, 24-h-Melatonin-Serumprofile bei Mammakarzinom-Patientinnen im Vergleich zu einer tumorfreien Kontrollgruppe, Geburtshilfe Frauen-heilkd. 56:589–595.CrossRefGoogle Scholar
  41. Hofstätter, R., 1959, Versuche der postoperativen Krebsbehandlung mit Zirbelstoffen, Krebsarzt 14:307–316.Google Scholar
  42. Huggins, C., Briziarelli, G., and Sutton, H., 1959, Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumor, J. Exp. Med. 109:25–42.PubMedCrossRefGoogle Scholar
  43. Itoh, M.T., Ishizuka, B., Kudo, Y., Fusama, S., Amemiya, A., and Sumi, Y., 1997, Detection of melatonin and serotonin N-acetyltransferase and hydroxyindole-O-methyltransferase activities in rat ovary, Mol. Cell Endocrinol. 136:7–13.PubMedCrossRefGoogle Scholar
  44. Jones, R.L., McGeer, P.L., and Greiner, A.C., 1969, Metabolism of exogenous melatonin in schizophrenic and non-schizophrenic volunteers, Clin. Chim. Acta. 26:281–285.PubMedCrossRefGoogle Scholar
  45. Kabuto, M., Namura, I., and Saitoh, Y., 1986, Nocturnal enhancement of plasma melatonin could be suppressed by benzodiazepines in humans, Endocrinol. Jpn. 33:405–414.PubMedCrossRefGoogle Scholar
  46. Karasek, M., Marek, K., Zielinska, A., Swietoslawski, J., Bartsch, H., and Bartsch, C., 1994, Serial transplants of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Fischer rats as model system for human breast cancer. 3. Quantitative ultrastructural studies of the pinealocytes and plasma melatonin concentrations in rats bearing an advanced passage of the tumor, Biol Signals. 3:302–306.PubMedCrossRefGoogle Scholar
  47. Karasek, M., Dec, W., Kowalski, A.J., Bartsch, H., and Bartsch, C., 1996, Serum melatonin circadian profile in women with adenocarcinoma of uterine corpus, Int. J. Thymology 4 (Suppl.l):80–83.Google Scholar
  48. Key, T.J., 1995, Hormones and cancer in humans, Mutat. Res. 333:59–67.PubMedCrossRefGoogle Scholar
  49. Khoory, R. and Stemme, D., 1988, Plasma melatonin levels in patients suffering from colorectal carcinoma, J. Pineal Res. 5:251–258.PubMedCrossRefGoogle Scholar
  50. Klein, D.C., 1985, Photoneural regulation of the mammalian pineal gland, in: Photoperiodism, melatonin, and the pineal, Ciba Foundation Symposium 117, (D. Evered and S. Clark, eds.), pp. 38–51, Pitman, London.Google Scholar
  51. Kvetnoi, I.M. and Levin, I.M., 1987, Daily excretion of melatonin in patients with cancer of the stomach and large intestine, Vopr. Onkol. 33:29–32.PubMedGoogle Scholar
  52. Laakso, M.L., Porkka Heiskanen, T., Alila, A., Stenberg, D., and Johansson, G., 1994, Twenty-four-hour rhythms in relation to the natural photoperiod: a field study in humans, J. Biol. Rhythms 9:283–293.PubMedCrossRefGoogle Scholar
  53. Lapin, V., 1974, Influence of simultaneous pinealectomy and thymectomy on the growth and formation of metastases of the Yoshida sarcoma in rats, Exp. Pathol. Jena. 9:108–112.PubMedGoogle Scholar
  54. Lapin, V. and Frowein, A., 1981, Effects of growing tumours on pineal melatonin levels in male rats, J. Neural Transm. 52:123–136.PubMedCrossRefGoogle Scholar
  55. Lee, C., Lapin, V., Oyasu, R., and Battifora, H., 1981, Effect of ovariectomy on serially transplanted rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene, Eur. J. Cancer Clin. Oncol. 17(7):801–808.PubMedCrossRefGoogle Scholar
  56. Lissoni, P., Brivio, F., Barni, S., Tancini, G., Cattaneo, G., Archili, C., Conti, A., and Maestroni, G.J., 1990, Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension, Anticancer Res. 10:1759–1761.PubMedGoogle Scholar
  57. Lissoni, P., 1997, Effects of low-dose recombinant interleukin-2 in human malignancies, Cancer J. Sci. Am. 3Suppl 1:S115–S120.PubMedGoogle Scholar
  58. Maestroni, G.J., 1993, The immunoneuroendocrine role of melatonin, J. Pineal Res. 14:1–10.PubMedCrossRefGoogle Scholar
  59. Markey, S.P., Higa, S., Shih, M., Danforth, D.N., and Tamarkin, L., 1985, The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion, Clin. Chim. Acta 150:221–225.PubMedCrossRefGoogle Scholar
  60. Moore, R.Y. and Klein, D.C., 1974, Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity, Brain Res. 71:17–33.PubMedCrossRefGoogle Scholar
  61. Morgan, P.J., Barrett, P., Howell, H.E., and Helliwell, R., 1994, Melatonin receptors: localization, molecular pharmacology and physiological significance, Neurochem. Int. 24:101–146.PubMedCrossRefGoogle Scholar
  62. Philo, R. and Berkowitz, A.S., 1988, Inhibition of Dunning tumor growth by melatonin, J. Urol. 139:1099–1102.PubMedGoogle Scholar
  63. Rowley, K.H. and Mason, M.D., 1997, The aetiology and pathogenesis of prostate cancer. Clin. Oncol. R. Coll. Radiol. 9:213–218.PubMedCrossRefGoogle Scholar
  64. Schmidt, U.E., 1996, Untersuchungen zum Einfluß des Tumorwachstums auf die Melatoninsekretion der Rattenzirbeldrüse, ph. D.Thesis at the Faculty of Chemistry and Pharmacy, University of Tübingen, Tübingen.Google Scholar
  65. Shah, P.N., Mhatre, M.C., and Kothari, L.S., 1984, Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods, Cancer Res. 44:3403–3407.PubMedGoogle Scholar
  66. Skene, D.J., Bojkowski, C.J., Currie, J.E., Wright, J., Boulter, P.S., and Arendt, J., 1990, 6-sulphatoxymelatonin production in breast cancer patients, J. Pineal Res. 8:269–276.PubMedCrossRefGoogle Scholar
  67. Tamarkin, L., Cohen, M., Roselle, D., Reichert, C., Lippman, M., and Chabner, B., 1981, Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)-anthracene-induced mammary tumors in the rat, Cancer Res. 41:4432–4436.PubMedGoogle Scholar
  68. Tamarkin, L., Danforth, D., Lichter, A., De Moss, E., Cohen, M., Chabner, B., and Lippman, M., 1982, Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer, Science 216:1003–1005.PubMedCrossRefGoogle Scholar
  69. Touitou, Y., Fevre, M., Lagoguey, M., Carayon, A., Bogdan, A., Reinberg, A., Beck, H., Cesselin, F., and Touitou, C., 1981, Age-and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man, J. Endocrinol. 91:467–475.PubMedCrossRefGoogle Scholar
  70. Yie, S.M., Brown, G.M., Liu, G.Y., Collins, J.A., Daya, S., Hughes, E.G., Foster, W.G., and Young-Lai, E.V., 1995, Melatonin and steroids in human pre-ovulatory follicular fluid: seasonal variations and granulosa cell steroid production, Hum. Reprod. 10:50–55.PubMedCrossRefGoogle Scholar
  71. Yoshida, R. and Hayaishi, O., 1984, Overview superoxygenase, Methods Enzymol. 106:61–70.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Christian Bartsch
    • 1
  • Hella Bartsch
    • 1
  1. 1.Centre for Research in Medical and Natural SciencesUniversity of TübingenTübingenGermany

Personalised recommendations